We use cookies for various purposes including enabling website functionality and targeted marketing activities. For more information about cookies, please review our Privacy & Cookie Notice.
Accreditation information
Target Audience
This activity is intended for oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists engaged in the care of patients with lung cancer.
Learning Objectives
- Integrate molecular profiling results, tumor characteristics, and individual patient factors into evidence-based treatment decisions for patients with lung cancer
- Appraise emerging clinical trial safety and efficacy data in order to guide individualized clinical decision-making in lung cancer care
- Evaluate and implement appropriate interventions to reduce and manage treatment-related adverse events that may occur during the course of lung cancer care
- Develop strategies to address barriers and enhance enrollment of both healthcare professionals and patients with lung cancer in clinical trials
Accreditation
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Bio Ascend. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To receive CME credit points, you MUST pass the posttest and complete the evaluation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
ALCS 2026 COI Faculty
Faculty Member
Financial Relationship(s)
Paul Bunn, MD
Executive Role: Board of Directors, Verastem
Jennifer Carlisle, MD
Consultant, Advisor, Speaker: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BlossomHill, Eli Lilly, Genentech/Roche, Gilead, ImmunityBio, Pharmacosmos
Jamie E. Chaft, MD
Shirish M. Gadgeel, MBBS, FASCO
Ryan Gentzler, MD
Researcher: Amgen, Arrivent, AstraZeneca, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Dizal, Eli Lilly, Janssen, Merck, Nalo Therapeutics, Pfizer, Prelude Therapeutics, Puma, Takeda, Tempus Consultant, Advisor, Speaker: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Genentech, GlaxoSmithKline
John V. Heymach, MD, PhD
Onkar V. Khullar, MD, MSc
Has no relevant financial relationships
Ticiana Leal, MD
Consultant, Advisor, Speaker: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Catalyst, Genentech, Gilead, Janssen, Jazz, Lilly, Molecular Therapeutics, Novocure, Nuvation Bio, Summit Therapeutics, Synthekine, Verastem Other: OncoC4
Abesh Niroula, MD
Has no relevant financial relationships
Kingsley Nnaewuba, MD
Has no relevant financial relationships
Suresh S. Ramalingam, MD, FACP, FASCO
Grant or Research Support to institution: Amgen, AstraZeneca, Bristol Myers Squibb, Gilead, Johnson & Johnson, Merck, Pfizer
Gregory J. Riely, MD, PhD
Joshua K. Sabari, MD
Consultant, Advisor, Speaker: AbbVie, AstraZeneca, EMD Serono, Genentech, Intuitive Surgical, Janssen/Johnson & Johnson, Jazz, Loxo Lilly, Mirati/Bristol Myers Squibb, Pfizer, Regeneron, Revolution Medicines, Sanofi Genzyme, Takeda Researcher: Boehringer Ingelheim, Janssen/Johnson & Johnson, Loxo Lilly, Mirati/Bristol Myers Squibb, ORIC, Regeneron
Rachel E. Sanborn, MD
Consultant, Advisor, Speaker: AbbVie Oncology, AstraZeneca, Boehringer Ingelheim, Curio Science, Daiichi Sankyo, Exelixis, Gilead, GlaxoSmithKline, IDEOlogy Health, Inhibrx, Janssen Oncology/Johnson & Johnson, Merck, MJH Life Sciences, Natera, Nuvation Bio, Pfizer, Rigel Therapeutics, Summit Therapeutics Other: BioAscend (honorarium); HotSpot Therapeutics (travel support); OSE Immunotherapeutics (Data Safety Monitoring Board)
Conor Steuer, MD
Consultant, Advisor, Speaker: Boehringer lngelheim, BMS, Caris, Daiichi Sankyo, Eli Lilly, EMD Serono, g1 Therapeutics, Merck, Mirati, Novocure, Regeneron, Sanofi
Sibo Tian, MD
Consultant, Advisor, Speaker: BioAscend, Castle Biosciences, Harbright Ventures, Merck/RTOG Foundation Researcher: Varian/Siemens Healthineers
Steering Committee
Steering Committee Member
Affiliation
Financial Relationship(s)
Ioana Bonta, MD
Georgia Cancer Specialists/Northside
Laercio Da Silva, MD
NIH/National Cancer Institute
Trevor Feinstein, MD
Piedmont Cancer Institute
Consultant, Advisor, Speaker: AstraZeneca, BeyondSpring, Daiichi Sankyo, Recordati, Sanofi
Aparna Kesarwala, MD, PhD
Emory/Winship
Onkar V. Khullar, MD, MSc
Emory/Winship
Has no relevant financial relationships
Mohan Krishnamachary, MD
Suburban Hematology-Oncology/Northside
Ticiana Leal, MD
Emory/Winship
Consultant, Advisor, Speaker: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Catalyst, Genentech, Gilead, Janssen, Jazz, Lilly, Molecular Therapeutics, Novocure, Nuvation Bio, Summit Therapeutics, Synthekine, Verastem Other: OncoC4
Kelsey Pan, MD
Emory/Winship
Consultant, Advisor, Speaker: AstraZeneca, Avyxa Pharma, Johnson & Johnson
Suresh S. Ramalingam, MD, FACP, FASCO
Emory/Winship
Grant or Research Support to institution: Amgen, AstraZeneca, Bristol Myers Squibb, Gilead, Johnson & Johnson, Merck, Pfizer
Instructions for Credit
To receive CE credit, learners must follow these steps:
- Link for activity evaluation coming soon
- Complete the activity evaluation
- Upon completion of all evaluation questions, your credit will be made available for download immediately.